Study summary · research use only
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review article discusses chronic hepatitis B virus (HBV) infection and thymalfasin (thymosin-alpha1). The authors describe the global burden of chronic HBV (approximately 350 million people, 75% in the Asia-Pacific region) and note that interferon-alfa and antiviral agents such as lamivudine and adefovir are used but with limited response, particularly in certain patient groups. They characterize thymalfasin as an immunoregulatory agent that enhances the Th1 response and report that it has been shown to trigger lymphocyte maturation, augment T-cell function, and promote reconstitution of immune defects. They state that monotherapy and combination studies with interferon are underway.
Abstract
Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its worldwide distribution and potential adverse sequelae. Globally, there are approximately 350 million people infected with chronic HBV, 75% of whom live in the Asia-Pacific region. Interferon-alfa and direct antiviral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in perinatally infected patients, patients with lower ALT levels and those with HBeAg-negative chronic hepatitis B. Thymalfasin (thymosin-alpha1) is an immunoregulatory agent able to enhance Th1 response. It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.